NCT07187778 2026-01-05
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06677190 2025-11-05
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07179770 2025-09-23
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
NYU Langone Health
Phase 1 Recruiting
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT04627064 2025-07-25
ABEMA Alone or in COMBO With MK-6482
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07023432 2025-06-17
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting